The University of Colorado Cancer Center welcomes Eric Clambey, PhD, as the new director of the Flow Cytometry Shared Resource (FCSR). Clambey, who is an assistant professor in the Department of Anesthesiology, is excited to take on his new role in a vital resource for the cancer center.
Born in Iowa and raised in Minnesota, Clambey attended St. Olaf College in Northfield, Minnesota and obtained a liberal arts education. It was there that he discovered his love of immunology. After college Clambey went to graduate school at Washington University in Saint Louis, where he completed a PhD in Immunology in 2002. He began his work as an assistant professor in the Department of Anesthesiology in 2012 at the CU School of Medicine.
“My research focuses on the dynamic interface between the immune system, inflammation and tissue repair,” Clambey explains. “In particular, my lab studies how T cells, pivotal cells of the immune system, influence the balance between health and disease at mucosal surfaces, including the lung and gastrointestinal tract.”
Many of his studies have utilized the FCSR to look at how cells behave across these different disease contexts. For clarification, flow cytometry is one tool that scientists have to study the behavior of individual cells. This technology has enabled cancer researchers to gain major insights into how cancer cells behave and how the immune system recognizes or fails to recognize cancer.
“The FCSR is a strong, vibrant Core that allows investigators across disciplines to access the power of flow cytometry. I have had the privilege of working with the CU Cancer Center Flow Core over many years,” Clambey explains. “Based on these experiences, I know first-hand how strong this core is, and how its oversight by Karen Helm, Flow Core Manager, has enabled it to remain at the forefront of this constantly evolving technology.”
Clambey, a self-proclaimed staunch advocate for the power of flow cytometric analysis, is enthusiastic about the future of the shared resource.
“I seek to both maintain the central strengths of this facility and to facilitate new strategic developments, including both instrumentation and data analysis. I am particularly excited about helping to bring new cutting-edge applications of cytometry to the cancer center,” he says. “With the development of new capabilities, I anticipate that the FCSR will remain a critical resource for researchers in the Cancer Center that empowers new scientific breakthroughs.”